Table 3 Estimates of cardiovascular events for the association with metabolic syndrome according to the number of traits in the Rivana cohort (n = 3,976)
Primary endpoint | Secondary endpoints | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Myocardial infarction, stroke, and mortality from cardiovascular disease | Myocardial infarction | Stroke | Mortality from cardiovascular disease | All-cause mortality | ||||||
Cases | 228 | 80 | 96 | 85 | 381 | |||||
Person- years of follow up | 47,838 | 48,215 | 48,227 | 48,629 | 48,629 | |||||
Incidence rate/1000 person-year | 4.77 | 1.66 | 1.99 | 1.75 | 7.83 | |||||
HR (95% CI)a | RAP (95% CI) | HR (95% CI)a | RAP (95% CI) | HR (95% CI)a | RAP (95% CI) | HR (95% CI)a | RAP (95% CI) | HR (95% CI)a | RAP (95% CI) | |
Number of traitsb | ||||||||||
0–1 trait | 1.00 (ref.) | 0.00 (ref.) | 1.00 (ref.) | 0.00 (ref.) | 1.00 (ref.) | 0.00 (ref.) | 1.00 (ref.) | 0.00 (ref.) | 1.00 (ref.) | 0.00 (ref.) |
2 traits | 1.87 (1.17–2.98) | 7.44 (1.67, 13.22) | 1.24 (0.63–2.43) | 3.84 (− 7.24, 14.92) | 3.02 (1.37–6.66) | 12.08 (2.79, 21.38) | 2.36 (0.88–6.35) | 6.64 (− 1.45, 14.73) | 1.56 (1.07–2.25) | 3.46 (− 0.03, 6.96) |
3 traits | 1.85 (1.16–2.95) | 7.31 (1.49, 13.14) | 1.01 (0.50–2.05) | 0.65 (− 10.73, 12.02) | 2.46 (1.10–5.50) | 9.99 (0.65, 19.34) | 3.06 (1.16–8.02) | 8.62 (0.60, 16.65) | 1.87 (1.30–2.68) | 5.17 (1.71, 8.63) |
4 traits | 2.06 (1.24–3.42) | 8.38 (2.00, 14.76) | 1.62 (0.77–3.43) | 7.78 (− 5.13, 20.68) | 2.36 (0.98–5.68) | 9.77 (− 0.31, 19.84) | 3.06 (1.11–8.45) | 8.54 (0.09, 16.99) | 1.88 (1.27–2.79) | 5.40 (1.63, 9.17) |
5 traits | 3.08 (1.67–5.69) | 13.51 (5.80, 21.23) | 2.36 (0.94–5.92) | 15.18 (− 1.05, 31.41) | 4.13 (1.51–11.24) | 15.41 (3.77, 27.06) | 4.20 (1.25–14.04) | 10.99 (1.11, 20.87) | 2.82 (1.74–4.57) | 8.80 (4.17, 13.42) |
Per additional trait | 1.22 (1.09–1.36) | 2.31 (0.88, 3.74) | 1.18 (0.98–1.42) | 2.88 (− 0.58, 6.35) | 1.20 (1.01–1.43) | 2.00 (0.04, 3.96) | 1.28 (1.06–1.56) | 1.88 (0.28, 3.49) | 1.22 (1.11–1.33) | 1.71 (0.84, 2.58) |